Population-level impact of weight loss on predicted healthcare spending and the incidence of obesity-related outcomes in the Asia-Pacific region: a modelling study
The financial, societal, and health benefits of a substantial but achievable 10% weight loss in adults living with obesity, and the consequences of insufficient action, are pronounced in the APAC region. To achieve sustained weight loss in the real world, policy actions for addressing barriers to obesity management are required.
Authors
- Gary Kilov (ORCID: https://orcid.org/0000-0002-8845-1468)
- Kyoung Kon Kim (ORCID: https://orcid.org/0000-0003-0374-2571)
- Joanne Yoong (ORCID: https://orcid.org/0000-0002-0162-9885)
- Sang Yeoup Lee (ORCID: https://orcid.org/0000-0002-3585-9910)
- Viswanathan Mohan (ORCID: https://orcid.org/0000-0001-5038-6210)
- Brian J. Oldfield (ORCID: https://orcid.org/0000-0002-8609-6589)
- Joseph Proietto (ORCID: https://orcid.org/0000-0002-8517-2076)
- Jack Garcia Uranga Romano
- Tushar Bandgar (ORCID: https://orcid.org/0000-0002-6902-4639)
- Wichai Aekplakorn (ORCID: https://orcid.org/0000-0002-3292-510X)
- Volker Schnecke (ORCID: https://orcid.org/0000-0002-8632-0923)
- Rajesh Khadgawat
- Sanjay Kalra
- Jamal Rashad Butt
Institutions
- The University of Melbourne (AU)
- Novo Nordisk (Denmark) (DK)
- King Edward Memorial Hospital and Seth G.S. Medical College (IN)
- Mahidol University (TH)
- Alexandra Hospital (SG)
- Australian Regenerative Medicine Institute (AU)
- Gachon University Gil Medical Center (KR)
- Madras Diabetes Research Foundation (IN)
- Dr. Mohan's Diabetes Specialities Centre (IN)
- Ramathibodi Hospital (TH)
- Pusan National University Yangsan Hospital (KR)
- Bharti Hospital (IN)
- All India Institute of Medical Sciences (IN)
Publication Details
- Journal
- BMC Global and Public Health
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1186/s44263-024-00094-x
- Citations
- 4
- Primary Topic
- Obesity, Physical Activity, Diet
- Type
- article
- Field-Weighted Citation Impact
- 2.17
Funders
- Novo Nordisk
- Novo Nordisk Pharma